Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents

Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer

(2014) R D Harvey   CLINICAL PHARMACOLOGY & THERAPEUTICS

Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09

(2013) A.B. Kimball et al.   BRITISH JOURNAL OF DERMATOLOGY

Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance

(2013) K-H Shin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

An update on drug–drug interactions with biologics for the treatment of moderate-to-severe psoriasis

(2013) Rishu Gupta et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Cutting Edge: IL-12 and Type I IFN Differentially Program CD8 T Cells for Programmed Death 1 Re-expression Levels and Tumor Control

(2013) M. Y. Gerner et al.   JOURNAL OF IMMUNOLOGY

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

(2013) Antonio Daponte et al.   Journal of Translational Medicine

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

(2013) Antoni Ribas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling

(2013) Marina Kacevska et al.   PHARMACEUTICAL RESEARCH

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

(2012) P. A. Prieto et al.   CLINICAL CANCER RESEARCH

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

(2012) John Dulos et al.   JOURNAL OF IMMUNOTHERAPY

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

(2012) Anna Maria Di Giacomo et al.   LANCET ONCOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

The growing challenge of obesity and cancer: an inflammatory issue

(2011) Alison E. Harvey et al.   Annals of the New York Academy of Sciences

Randomized Phase II Trial of Sulindac, Atorvastatin, and Prebiotic Dietary Fiber for Colorectal Cancer Chemoprevention

(2011) P. J. Limburg et al.   Cancer Prevention Research

Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis

(2011) C Schmitt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cytochrome P450 2C9 mediated metabolism in people with and without cancer

(2011) S.S. Shord et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Cytochrome P450-derived eicosanoids: the neglected pathway in cancer

(2010) Dipak Panigrahy et al.   CANCER AND METASTASIS REVIEWS

Pattern Recognition Receptors and Inflammation

(2010) Osamu Takeuchi et al.   CELL

Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression

(2010) Eek Joong Park et al.   CELL

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

Activation of the Acute Inflammatory Response Alters Cytochrome P450 Expression and Eicosanoid Metabolism

(2010) K. N. Theken et al.   DRUG METABOLISM AND DISPOSITION

Intracellular Toll-like Receptors

(2010) Amanda L. Blasius et al.   IMMUNITY

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

(2010) Evan M. Hersh et al.   INVESTIGATIONAL NEW DRUGS

Identification and functions of pattern-recognition receptors

(2010) Yutaro Kumagai et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Monocytes and Macrophages Regulate Immunity through Dynamic Networks of Survival and Cell Death

(2010) Arti Parihar et al.   Journal of Innate Immunity

Modulation of Hepatic Cytochrome P450s by Citrobacter rodentium Infection in Interleukin-6- and Interferon- -Null Mice

(2010) B. A. Nyagode et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Signaling Through OX40 Enhances Antitumor Immunity

(2010) Shawn M. Jensen et al.   SEMINARS IN ONCOLOGY

The Effect of Infliximab on Hepatic Cytochrome P450 and Pharmacokinetics of Verapamil in Rats with Pre-Adjuvant Arthritis: A Drug-Disease and Drug-Drug Interaction

(2009) Spencer Ling et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics

(2009) ET Morgan   CLINICAL PHARMACOLOGY & THERAPEUTICS

Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity

(2009) Ursula Lutz et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer

(2008) E. T. Morgan et al.   DRUG METABOLISM AND DISPOSITION

Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing

(2008) Marina Kacevska et al.   Expert Opinion on Drug Metabolism & Toxicology

Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice

(2008) Juliana Hamzah et al.   JOURNAL OF CLINICAL INVESTIGATION

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

(2008) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA